Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need.
Location: United States, Massachusetts, Lexington
Employees: 51-200
Total raised: $79M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Foresite C... | foresiteca... |
| - | OrbiMed | orbimed.co... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.03.2020 | Series C | $56M | - |
| 08.01.2019 | Series B | $23M | - |
Mentions in press and media 19
| Date | Title | Description |
| 05.03.2024 | Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference | - |
| 14.12.2021 | Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hemato... | Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase 2, Open-Label, Ascending Dose Study... |
| 14.12.2021 | Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hemato... | Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition Lexin... |
| 13.12.2021 | Keros Therapeutics : Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annu... | Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition •Keros Therapeut... |
| 13.12.2021 | Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual... | Keros Therapeutics will be hosting a conference call and webcast today, December 13, 2021, at 4:01 p.m. ET. LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceu... |
| 10.12.2021 | Keros Therapeutics : Investor Call Presentation | KER-050 Update 13 December 2021| CONFIDENTIAL Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litig... |
| 04.11.2021 | Corporate Presentation November 2021 | Corporate Presentation November 2021 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Ref... |
| 22.06.2021 | Keros Therapeutics : KER-050 Update | KER-050 Update 23 June 2021 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act o... |
| 22.06.2021 | Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes | LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients s... |
| 07.05.2021 | KEROS THERAPEUTICS, INC. Keros Therapeutics : Corporate Presentation May 2021 | Corporate Presentation May 2021 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform A... |
Show more